Navigation Links
Different Types Of Multiple Sclerosis May Be Treated Differently

Researchers from the Mayo Clinic had demonstrated that there are differences in pathological subtypes of multiple sclerosis that may react differently to treatment. Only those multiple sclerosis (MS) patients with evidence for antibody deposition or complement activation // -- immune cells that can cause tissue destruction -- in their lesions are likely to respond to plasma exchange, a treatment for acute MS attacks.

The research findings will be published in the August issue of The Lancet.

During plasma exchange treatment, the patient’s blood is removed and the blood cells are mechanically separated from the fluid plasma. The patient’s blood cells are then mixed with replacement plasma and the mixture is returned to the patient. Researchers had previously found plasma exchange might help restore neurological function in approximately 45 percent of those experiencing sudden, severe MS attacks whose resulting disabilities did not respond to high doses of steroid treatment.

The study was conducted retrospectively in an attempt to unravel the “all or none” response Mayo Clinic MS experts had witnessed with plasma exchange treatment for acute attacks in 19 patients who at one point had undergone a brain biopsy in the course of their disease when the diagnosis of MS was still in question. Patients were seen at Mayo Clinic, the University of Vermont or a European center, and all included in the study had severe disabilities, including paralysis and loss of speech, which failed to improve with standard anti-inflammatory steroid treatment. Since tissue was already available on these patients, researchers had classified their lesions into four patterns based on the types of immune cells present and the pattern of myelin injury.

The investigators found that the 10 patients with pattern II MS lesions contain large quantities of immunoglobulin (proteins that serve as antibodies) and complement activation (the ability to combine wit h antibodies to destroy tissue) experienced moderate to marked improvement after treatment with plasma exchange. These patients experienced major gains in cerebral, motor, brain stem/cranial nerve, cerebellar and/or sensory function. Improvement began after an average of three days. However, none of the MS patients with lesions typical of either patterns I or III, which lack evidence for antibody or complement activation, achieved such improvement.

The investigators postulate that only the pattern II MS patients’ attacks responded to treatment because of the way in which plasma exchange works -- by removing disease-causing factors in the blood and plasma, such as antibodies and complement, which are only present in pattern II MS lesions.

Source: Newswise, The Lanet

Related medicine news :

1. Different Sun Rays, Different Damage
2. Heart Attack Symptoms Different in Women
3. The Cause Of Visual Problems Different From Race To Race
4. Different Drug May Help Children With Duchenne Muscular Dystrophy
5. Learning Just How Different We Are
6. Have You Ever Wondered How We Perceive Different Sounds?
7. Resident Physicians Need More Preparations To Treat Patients From Different Cultures
8. Differentiated Thyroid Carcinoma Can Widely Infiltrate The Larynx
9. Men Use Their Brain Differently From Women
10. Alcohol Is Responsible For 60 Different Diseases
11. Different Parts Of The Brain Are Involved In Memory Retention
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology: